Kornimate/medical-research-clean huggingface dataset:
children's use of the built environment for physical activity

Conditions: Obesity; Overweight

Summary: the study aims are to develop and test the feasibility of a pediatric physical activity intervention that incorporates personal information on use of the built environment, and test the intervention's preliminary efficacy at increasing physical activity. the investigators hypothesize that it will be feasible to incorporate and measure changes in empiric gis (geographic information system), gps (global positioning system), and accelerometer feedback in the office setting as demonstrated by: i) completeness of gps and accelerometer data collection (primary measure of feasibility), ii) participation rates among adolescents in the intervention group compared to the control group, and iii) acceptability to patients as measured by adolescent satisfaction.


Eligibility criteria:
inclusion criteria: * adolescents ages 10-16 years * bmi \> 85th percentile for age and sex exclusion criteria: * physical conditions impairing ambulation * adolescents who do not speak english * adolescents who have missed more than 2 scheduled doctor's appointments during the past 5 years * adolescents who are receiving any other form of physical activity counseling/intervention at the time of enrollment

Keywords: obesity overweight physical activity built environment counseling
comparative analysis of incidence of newly developed postoperative low back pain with field block versus without field-block before spinal anaesthesia for patients undergoing caesarean sections

Conditions: Caesarean Section

Summary: the study aimed to evaluate the effectiveness of field block in preventing postoperative low back pain (pdpb) in patients undergoing cesarean sections.

the purpose of this study was to evaluate the effectiveness of field block with lidocaine 2% (5 ml) administered with a 24g hypodermic needle before spinal anesthesia for patients undergoing lscs, in preventing the development of postoperative low back pain (pdpb). the study aimed to determine if using a field block would decrease the incidence of pdpb compared to patients who received only spinal anesthesia.

Eligibility criteria:
inclusion criteria: all patients undergoing lscs under spinal anesthesia, asa grade 2 and grade 2e and willing to participate in the trial exclusion criteria: spine pathology/instability and coagulopathy, asa grade 3 and above, pre-exiting low back pain, morbid obesity (bmi \&gt; 35), patients needing more than 1 attempt for administration of spinal anaesthesia, patients utilizing labour analgesia, local infection or inflammation at the site of spinal anesthesia/field block, unwilling to participate -

Keywords: cesarean section back pain anesthesia, local anesthesia, spinal lidocaine
reducing eco-anxiety using selfies

Conditions: Ecology; Anxiety

Summary: the purposes of this study are to test among adolescent viewers the utility of selfie (tiktok) short video-based interventions to: 1. reduce ecological anxiety, 2. increase ecological agency, 3. compare two different types of messaging, and 4. examine the role of viewer's gender and race as independent factors on the outcomes of interest.

intervention videos will each be tiktok self-recorded videos (of 58-second duration) featuring the same underage professional (ages 16) acting as simulated participant. video 1 ("negative") will focus on impending ecological catastrophic outcomes; video 2 ("positive") will focus on the actions that youth will be able to take in preventing such outcomes; and video 3 ("neutral") will include content unrelated to ecological concerns. we intend to assign \~1,000 individuals aged 14-18 in a randomized way, in equal proportions, and stratified by sex and race, to view one of the three tiktok videos: positive, negative, or neutral. assessments will occur at baseline and post-intervention, and will include: 1. demographics (baseline only), 2. primary outcome: a. climate change anxiety scale (13 items) 3. secondary outcome: 1. climate hope scale (11 items) 2. behavioral intentions (6 items; adapted from)29, 3. hopefulness and agency sliders (2 items), and 4. three words

Eligibility criteria:
inclusion criteria: * english-speaking * living in the us * ages 14 - 18 exclusion criteria: * none
assessing the ability of the t-spot®.tb test

Conditions: Tuberculosis (TB)

Summary: the primary objective of this clinical research study is to demonstrate performance of the normalized tb specific lymphocyte response in identifying patients with active tb disease. the secondary exploratory objective is to demonstrate that active tb cannot be identified using an antigen-to-mitogen ratio derived from an elisa-based igra.

the target number of subjects is 100 active tb and 100 active tb excluded . this study will enroll up to 680 subjects (based on previous enrolment rates of approximately 300-350 subjects enrolled for 50 active tb and 50 active tb excluded). study duration: 6 months all subjects enrolled in this study will be men or women, aged 18 years or older.

Eligibility criteria:
inclusion criteria: cohort 1a and 1b * • must be at least 18 years of age * must be able to provide informed consent * must be able to provide a minimum of 10 ml of whole blood at each visit (16ml for immunocompromised i.e. hiv+) * must be t-spot.tb positive * first visit suspect tb subjects with no prior history of tb diagnosis inclusion criteria: cohort 2a and 2b * must be at least 18 years of age * must be able to provide informed consent * must be able to provide a minimum of 10 ml of whole blood at each visit (16ml for immunocompromised i.e. hiv+) * must be t-spot.tb positive * no prior history of tb diagnosis exclusion criteria: cohort 1a and 1b * • negative in the t-spot.tb test * previous or pre-existing confirmed tb diagnosis * on anti-tb treatment for more than 1 week\* * not meeting inclusion criteria exclusion criteria: cohort 2a and 2b * negative t-spot.tb test * previous or pre-existing confirmed tb diagnosis * on anti-tb treatment * symptoms of active tb * not meeting inclusion criteria

Keywords: tb
a randomised trial to evaluate the antiviral efficacy and safety of treatment with 500 mg tipranavir (tpv) plus 100 mg or 200 mg ritonavir (rtv) p.o. bid in comparison to 400 mg lopinavir (lpv) plus 100 mg rtv p.o. bid in combination with standard background regimen in arv therapy naïve patients.

Conditions: HIV Infections

Summary: evaluation of safety and efficacy of tipranavir (tpv) boosted with ritonavir (rtv) versus an active control arm (lopinavir / rtv) in antiretroviral (arv) therapy naïve hiv-1 infected patients


Eligibility criteria:
inclusion criteria: 1. signed informed consent prior to trial participation. 2. hiv-1 infected males or females \>= 18 years of age. 3. no previous arv therapy. 4. any cd4+ t lymphocyte count \< 500 cells / µl. 5. hiv-1 viral load \>= 5000 copies/ml at screening. 6. screening laboratory values that indicate adequate baseline organ function. 7. a prior aids defining event is acceptable as long as it has resolved or the subject has been on stable treatment (e.g. opportunistic infection; no arv) for at least 2 weeks before screening exclusion criteria: 1. female patients of child-bearing potential who: * have a positive serum pregnancy test at screening or during the study, * are breast feeding, * are planning to become pregnant 2. use of investigational medications within 30 days before study entry or during the trial
safety and efficacy of bemiparin in the prevention of thrombotic events in hospitalized cirrhotic patients

Conditions: Cirrhosis and Coagulation

Summary: prospectively evaluation of the incidence of thromboembolic events in hospitalized cirrhotic patients. 2. efficacy and safety of use of bemiparin in preventing peripheral and portal thrombosis. 3. monitoring antixa levels.

primary objective: to evaluate the safety of prophylactic anticoagulation bemiparina (hibor®) for the prevention of peripheral and portal vein thrombosis in cirrhotic patients with prolonged hospitalization. secondary objectives are the following: 1. to evaluate the incidence of thrombotic events in hospitalized cirrhotic patients. 2. to evaluate the efficacy of low molecular weight heparin (hibor 3.500ui) in preventing thrombotic events in hospitalized cirrhotic patients. 3. to identify risk factors for development of portal vein thrombosis and deep vein thrombosis in hospitalized patients. 4. evaluate the morbidity and mortality associated with thromboembolic events. 5. evaluate prophylactic anticoagulation levels by determining antixa and antithrombin iii. 6. to study the expression profile and functionality of toll-like receptors as factors intimately involved in the inflammatory response, as well as the variability of different serum markers associated with proinflammatory state: i-fabp / il6-il8 / no, endothelin and lps-binding protein. 7. evaluate the effect on liver fibrosis (by fibroscan®) and serum tgf 8. evolution of hepatocellular function estimated by the scores of child-pugh and meld.

Eligibility criteria:
inclusion criteria: 1. liver cirrhosis of any etiology diagnosed by previous biopsy or clinical, laboratory and sonographic criteria 2. hospital admission at least 3 days, because of decompensated liver disease (ascites, encephalopathy, controlled gastrointestinal bleeding, spontaneous bacterial peritonitis) 3. signed written consent 4. women of child-bearing age use effective contraception exclusion criteria: 1. age \ 80 years 2. contraindication to treatment with heparins 3. uncontrolled hemorrhage 4. any comorbidity involving a therapeutic limitation and / or a life expectancy \<6 months 5. concomitant antiplatelet therapy (aspirin, clopidogrel, ticlopidine, dipyridamole, sulfinpyrazone, dextran 40, or other anticoagulants 6. and continued concomitant nsaids, salicylates, corticosteroids 7. existence of clinically significant esophageal varices / severe gastropathy of portal hypertension without their having been previously treated with primary / secondary prophylaxis (endoscopic variceal ligation / non cardioselective beta blockers) 8. refusal to participate in the study, or to sing informed consent 9. pregnancy or lactation 10. hiv infection 11. platelet count \<20,000 platelets / dl 12. renal clearance below 30ml / min 13. portal vein thrombosis or peripheral thrombosis diagnosed at admission 14. presence of procoagulant factor previously known
women at risk of breast cancer and olfm4

Conditions: Hereditary Breast and Ovarian Cancer Syndrome

Summary: does the olfactomédine provide an help to limit the number of false positives in the overall imaging balance and limit the number of unnecessary biopsies?

about 5% of breast cancers are associated with the presence of a constitutional genetic alteration. two genes are being studied: brca1 and brca2. the national program for breast cancer screening target women 50 to 74 years but does not include women with significant risk factors. however in identifiable risk situations, breast cancer incidence is increased: and it affects 1 in 4 women with certain risk histological lesions and more than 1 in 2 women carrying a mutation in the brca1 or brca2 gene. studies have shown that the olfactomédine 4 (olfm4) is highly overexpressed in tumors compared to healthy tissue. the olfm4 might therefore be a marker for early detection of breast cancer. we wish to determine the positive predictive value of olfm4 seric dosing of patients at risk with respect to imaging.

Eligibility criteria:
inclusion criteria: * age \> or = 18 years * high risk women of breast cancer occurrence defined by the following criteria: * women carrying a genetic mutation brca1 or 2 or tp53, entering or already in screening breast irm * women with a high probability of hereditary predisposition to breast cancer (20% risk at 70 years of breast cancer by boadicea model), assessed by the onco-geneticists * information of the person and signing the informed consent exclusion criteria: * women with a history of breast cancer or in situ * person who is not affiliated to a social security scheme or beneficiary of such a regime

Keywords: high risk of cancer, brca1 or 2 mutation, olfactomedine 4
exploration of the biologic basis for underperformance of oral polio and rotavirus vaccines in india (provide)

Conditions: Poliomyelitis; Tropical Enteropathy

Summary: oral polio and rotavirus vaccines are significantly less effective in children living in the developing world. tropical enteropathy, which is associated with intestinal inflammation, decreased absorption and increased permeability, may contribute substantially to oral vaccine failure in developing country settings. other possible causes of oral vaccine underperformance include malnutrition, interference with maternal or breast milk antibodies, changes in gut microbiota, and genetic susceptibility.the primary objective of this study is to determine whether decreased vaccine responsiveness to oral poliovirus or rotavirus vaccines is associated with the presence of tropical enteropathy.

intervention of this study is to vaccinate oral poliovirus vaccine and oral rotavirus vaccine to the child with two group; with inactivated poliovirus vaccine and without inactivated poliovirus vaccine. rotavirus vaccines give to the child at 10 weeks of age and 17 weeks of age.

Eligibility criteria:
inclusion criteria: 1. mother willing to sign informed consent form. 2. infant aged 0 to 49 days old. 3. no obvious congenital abnormalities or birth defects. exclusion criteria: 1. parents are not willing to have child's blood drawn. 2. parents are planning to enroll child into another clinical study during the time period of this trial. 3. mother not willing to have blood drawn and breast milk extracted. 4. parents not willing to have field research assistant in home. 5. history of seizures or other apparent neurologic disorders. 6. infant does not have proof of bcg and opv since birth by immunization card. 7. history of acute illness and/or immunocompromised state of the child. 8. immunocompromised or chronically ill mother

Keywords: oral vaccines vaccine responsiveness tropical enteropathy
ai-assisted preoperative planning technology for tha for ddh

Conditions: Developmental Dysplasia of the Hip

Summary: in this study, the investigators retrospectively collected ddh case data of tha assisted by ai 3d planning and tha assisted by traditional planning. the compliance between preoperative planning and the type of prosthesis used in the operation, the position of the acetabular prosthesis, the correction of lld and the postoperative joint function score were analysed to evaluate the short-term effect of ai combined with preoperative 3d planning in tha for ddh.


Eligibility criteria:
inclusion criteria: * ddh was diagnosed by clinical signs and imaging examination, and a primary tha was planned; * the patient had persistent unilateral hip pain, which seriously affected their quality of life; * the standard posterolateral approach was used; * the contralateral hip was normal or had received tha; * the proximal femoral dorr classification was type a or b; * the acetabular classification was crowe type ⅰ, ⅱ, ⅲ or iv; * all patients were treated with the bioartificial hip joint pinnacle® cup or summit® stem, developed by johnson \& johnson biological. exclusion criteria: * preoperative and postoperative imaging examinations did not meet the evaluation criteria (non-standard double-hip anteroposterior film, acetabular angle and ll length could not be accurately measured); * severe osteoporosis, tumour or metabolic disease around the affected hip joint; * spinal deformity by other causes or a history of lumbar internal fixation; * external deformity of the affected hip joint in the lower extremity; * neuromuscular insufficiency (with hip abduction weakness and poliomyelitis); * severe disease with intolerance to surgery.
genes causing ebstein's anomaly

Conditions: Heart Septal Defects, Ventricle; Heart Defects, Congenital; Double Outlet Right Ventricle; Truncus Arteriosus, Persistent

Summary: this study will investigate ebstein's anomaly, a congenital abnormality of the tricuspid valve of the heart and try to identify the genetic origins of the disease. adults and children 2 years of age and older with ebstein's anomaly and healthy volunteers may be eligible for this study. participants undergo the following procedures: * blood tests: three tube of blood will be collected, with the total amount limited to about half a teaspon for each two pounds of body weight. * saliva sample collection: a small amount of saliva is collected by spitting into a sterile container. * oral (cheek) swab: cells are collected from the mouth using a soft brush to swab the inside lining of the cheek. * electrocardiogram: the electrical activity of the heart is recorded using electrodes placed on the chest. * echocardiogram: heart function is assessed using ultrasound.

the goal of this study is to elucidate the genetic basis for the congenital heart disease (chd) known as ebstein's anomaly. these studies complement ongoing research studies using mouse models to recover mutations causing structural heart defects associated with human chd. by elucidating the underlying genetic causes for ebstien's anomaly, it may be possible to improve risk assessments as well as facilitate the development of new strategies for prevention and disease management. these studies are important for early diagnosis and the management of complications associated with surviving adults with ebstein's anomaly, some of whom have undergone surgical correction and others that are unoperated.

Eligibility criteria:
* inclusion criteria: patients who have diagnosed ebstein's anomaly or tricuspid valve disease in belarus or ukraine and their parents will be asked to participate in this study regardless of sex, age, or race. in addition, sex and age matched neighborhood children and their parents will be recruited as controls. there is no known ethnic or racial predilection for ebstein's anomaly or tricuspid valve disease. exclusion criteria: there are no exclusion criteria. this may allow us to discover previously unknown relationships between ebstein's anomaly and other diseases.

Keywords: ebsteins anomaly heart septal defects, ventricle heart defects, congenital double outlet right ventricle truncus arteriosus persistant ebstein's anomaly congenital heart disease heart defects
evaluation of laser and tranexamic acid in treatment of melasma

Conditions: Melasma

Summary: melasma is an acquired, chronic, recurrent, symmetrical hypermelanosis, which is characterized by brown patches of variable darkness on sun exposed areas of the body. it is more common in women. it is common psychologically and emotionally distressing cosmetic problem in affected patients .

many studies examined multiple treatment options for melasma , but none of them is completely satisfactory with recurrence in most cases. tranexamic acid is is a relatively new drug for melasma . it is currently used via a spectrum of delivery routes including oral, topical, intradermal, and microneedling . laser-assisted drug delivery (ladd) is a technique that facilitates the delivery of topical medications . on reviewing the previous literatures, few studies have focused on therapeutic effects of combined laser and txa (topical and intradermal) in melasma, with variations in parameters of laser, in dose, concentration, form and routes of txa application; and in follow up duration. these studies revealed variable unproven results, and since melasma is a challenging disease, additional studies are needed to determine the optimal laser parameters and the best absorbable topical txa formula, ensuring the best efficacy and less complications. to the best of our knowledge, this is the first study that will use topical txa gel as an additive effect between sessions, and to confirm the effect of laser and txa by histopathology and immunohistochemistry.

Eligibility criteria:
inclusion criteria: * - gender: only female patients. * age: 18-50 years old. * type of melasma: bilateral symmetrical facial melasma of all types. * fitzpatrick skin phototypes: types iii, iv and v. exclusion criteria: * - pregnancy and lactation. * patients taking oral contraceptive pills, hormonal replacement therapy or isotretinoin at the time of the study or during the past 6 months. concomitant use of anticoagulants, bleeding disorders. * scarring and keloid tendency, active skin infections, active hsv, and those with facial cancer. * history of photosensitivity or photosensitizing medications such as sulfonamides and tetracycline. * previous history of post inflammatory hyperpigmentation.
treatment of leishmaniasis with impavido® (miltefosine): higher-weight patient registry

Conditions: Leishmaniasis

Summary: this study is a prospective observational study in which patients undergoing treatment for leishmaniasis with miltefosine (impavido) in the us and who weigh \> 75 kg can volunteer to provide information about their clinical response to treatment up to 6 months after the start of treatment.

objective: the purpose of this observational study is to fulfill pmr 2127-4 for the miltefosine nda (204684): implement a higher-weight-patient registry for the time period mar 2015-mar 2020. study design: this study is a prospective observational study in which patients undergoing treatment for leishmaniasis with impavido in the us and who weigh \> 75 kg can volunteer to provide information about their clinical response to treatment up to 6 months after the start of treatment. population: leishmaniasis patients treated with impavido who weigh more than 75 kg. drug product: drug name: impavido (50 mg capsules). dosing regimen: as per the impavido product label study procedures: patients who weigh more than 75 kg will become aware of the impavido higher-weight patient registry via the impavido website. by calling 1-866-588-5405, the patient will be connected to the impavido higher-weight patient registry coordinating center. a trained staff member will acquaint the patient with the goals and procedures of the study. if the patient tentatively agrees to participate in the study over the telephone, the patient will be mailed information forms, the consent/assent forms, and the consent for the patient's physician to release medical information. receipt of the two signed consent and/or assent forms by the coordinating center will signify patient consent. the coordinating center will contact the patient's physician at the end of treatment, and at 1, 3, and 6 months after completing treatment, to collect data on efficacy and adverse effects (only during treatment). sample size and study duration: estimated 3-10 patients per year for 5 years. outcome parameters: efficacy adverse effects analysis: baseline data, compliance to prescribed treatment, and outcomes will be reported for individual patients and for all patients.

Eligibility criteria:
inclusion criteria: 1. did the subject give consent to collect data from her or her physician? 2. was the subject treated for leishmaniasis with miltefosine? 3. does the subject weigh more than 75 kg? exclusion criteria: \[none\]
the disease severity in patients with psoriasis

Conditions: Psoriasis

Summary: this observational study aims to evaluate new markers to predict disease activity in psoriasis. the main question is sgot, sgpt, ggt, hs-crp, and apo b related to disease severity in psoriasis.

psoriasis patients who had signed an informed consent were assessed for pasi scores and 5 cc of blood was drawn for ggt, hs-crp, and apo b examinations. a pasi score is a tool used to measure the severity and extent of psoriasis. pasi is an acronym for psoriasis area and severity index.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of psoriasis exclusion criteria: * heart failure * diabetes mellitus * kidney disease

Keywords: psoriasis psoriasis area and severity index gamma-glutamyl transferase crp apolipoprotein b